focus -WSS

focus

author：explore 2025-09-30 01:02:47 - browse：779

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s ALS treatment — the latest potential turning point for a drug that has seen its share of ups and downs with regulatory bodies.

In June, a European Medicines Agency committee issued a negative review of Amylyx’s drug, called Albrioza, and cast doubt on whether it had demonstrated effectiveness in its pivotal study. That would have almost certainly led to a rejection by regulators, but Amylyx requested what’s called a re-examination of the opinion. On Tuesday, the EMA held a meeting on the appeal, and a decision is expected in the coming weeks.

“There are patients who are dying and they really want access to the drug,” said Evy Reviers, the chairwoman of the European Organization for Professionals and Patients with ALS, whose father has the neurological disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： The biotech scorecard for Q1: 17 stock

entertainment

focus

WSS

Biotech venture capitalists face new demands from investors

Humana cuts profit projections as Medicare Advantage costs soar

Eli Lilly, Pfizer, and others want in on the online prescription market

Independent physicians launch a new lobbying group

NIH director takes cautious approach to Biden drug pricing priority

AI generated plenty of interest at JPM but not a lot of trust

Wikipedia

focus

focus

Heart attack and stroke risk calculators need revising

Think you might have Covid

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

BioMarin wins approval for gene therapy to treat hemophilia A

Ahead of JPM, here's who's profiting most in health care

Psychedelics group wrestles with new pharma identity

3 medical device trends to watch in 2024

Novavax promises a turnaround & Lilly roils the obesity market

New weight loss drugs work. But how can they best be used?

hotspot

J&J to buy cancer drug developer Ambrx Biopharma

Chronically ill young patients struggle to find fertility info

FDA clears AI tool for detecting skin cancer

Research misconduct: Proposed new rules face resistance

Elizabeth Holmes banned from government health programs

Ahead of JPM, here's who's profiting most in health care

knowledge

entertainment

focus

leisure time